<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1620">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140070</url>
  </required_header>
  <id_info>
    <org_study_id>PreSTFibre4kids</org_study_id>
    <nct_id>NCT05140070</nct_id>
  </id_info>
  <brief_title>Fruit and Vegetable Products Enriched With Fibre From Potato Starch With Prebiotic Properties for Children and Youth</brief_title>
  <official_title>Development and Implementation of an Innovative Technology for the Production New Generation Fruit and Vegetable Products Enriched With Dietary Fibre Preparation From Potato Starch With Prebiotic Properties for Children and Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Memorial Health Institute, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jan Dlugosz University of Czestochowa, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tymbark MWS Sp. with o.o. Sp. K., Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Center-Institute of Maria Skłodowska - Curie, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Memorial Health Institute, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the project is to test fruit and vegetable mousse, with the addition of a&#xD;
      fiber preparation made of potato starch with prebiotic properties, on selected clinical,&#xD;
      metabolic and immunological parameters in overweight and obese children.&#xD;
&#xD;
      The study will be performed in a group of 80 to 100 children aged 6 to 10 years (pre-pubertal&#xD;
      age), using a double-blind procedure. Children will be randomly assigned into two groups,&#xD;
      i.e. the intervention group (they will receive a vegetable and fruit mousse with the addition&#xD;
      of potato starch fiber preparation with prebiotic properties) and the control group (they&#xD;
      will receive an identical preparation in their diet, but without the addition of potato&#xD;
      starch fiber preparation).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose and nature of the study:&#xD;
&#xD;
      The study financed by the National Center for Research and Development is aimed at examining&#xD;
      the vegetable and fruit mousse with the addition of a potato starch fiber preparation with&#xD;
      prebiotic properties, in terms of preventing overweight and obesity in children and limiting&#xD;
      the occurrence of metabolic disorders secondary to obesity.&#xD;
&#xD;
      Description of the procedures Children participating in the study will consume a daily fruit&#xD;
      and vegetable mousse with or without the addition (control group) of a fiber-based potato&#xD;
      starch preparation with prebiotic properties. Random selection will decide whether child will&#xD;
      consume vegetable and fruit mousse with the addition of a fiber-based potato starch&#xD;
      preparation with prebiotic properties. The study will be double blinded: neither parent and&#xD;
      child, nor the attending physician will know whether the consumed mousse contains a fiber&#xD;
      preparation. This method of conducting the study (random selection to the study group and&#xD;
      control group and the so-called study blind) aims to eliminate the attitude of both the study&#xD;
      participant and the observer to the therapy, which could affect the final assessment.&#xD;
&#xD;
      Children will take the mousse every day for six months (6 months). In order to evaluate the&#xD;
      effect of fruit and vegetable mousse with the addition of a fiber preparation made of potato&#xD;
      starch with prebiotic properties, the following tests will be performed: measurements of&#xD;
      height, weight and, based on this measurements body mass index (BMI) will be calculated,&#xD;
      waist circumference and blood pressure, bioimpedance test to assess the content of adipose&#xD;
      and muscle tissue in the body, ultrasound of the carotid vessels and the liver, the speed of&#xD;
      the pulse wave using the oscillometric method, the elastographic examination with a&#xD;
      fibroscan, the examination of the composition of the intestinal flora in a stool sample, and&#xD;
      a venous blood sample (7-10 ml volume) will be taken to evaluate lipid, carbohydrate&#xD;
      metabolism, liver function, adipose tissue function, antioxidant status, and immune response&#xD;
      parameters. The mentioned tests will be performed three times during the observation, i.e. at&#xD;
      the time of enrollment in the study, after 6 months of taking the fruit and vegetable mousse&#xD;
      and 3 months after the end of the vegetable and fruit mousse. In connection with&#xD;
      participation in the study, the Child and Parents will be provided with dietary and physical&#xD;
      activity advice as well as psychologist's advice on the day of enrollment in the study and at&#xD;
      3-month intervals up to 9 months from the start of participation in the study. Additionally,&#xD;
      3 months after starting taking the fruit and vegetable mousse, anthropometric and blood&#xD;
      pressure measurements will be performed. During the participation in the study possible side&#xD;
      effects will be registered.&#xD;
&#xD;
      A questionnaire containing questions about the child's date of birth, questions about the&#xD;
      child's general health and taking medications, about the socio-demographic situation of the&#xD;
      family, and food frequency questions will be completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomize, double blind, intervention vs control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>the same appearance of the mousse (with and without active substance)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BMI z-score change</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>Change in age and sex standardized BMI z-scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioimpedance</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>Change in body composition on bioimpedance (fat-body-mass %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>Change in waist z-score (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in microbiome composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in triglyceride-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in cholesterol-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein (LDL)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in Low-density lipoprotein (LDL)-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein (HDL)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in high-density lipoprotein (HDL)-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>very low-density lipoprotein (VLDL)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in very low-density lipoprotein (VLDL)-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in apolipoprotein-parameter of lipid metabolism (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uric acid</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in uric acid (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptin</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in leptin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in adiponectin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose, serum</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in glucose (mg%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin, serum</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in insulin (mcIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), score, normal range&lt;2,5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione (GSH)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in Glutathione (GSH) (g Hgb/mcL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glutathione peroxidase (GPx)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in glutathione peroxidase (GPx) (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total antioxidant status (TAS)</measure>
    <time_frame>6 to 9 months</time_frame>
    <description>change in total antioxidant status (TAS) (mcmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis factor α (TNF-alfa)</measure>
    <time_frame>6 months</time_frame>
    <description>change in tumor necrosis factor α (TNF-alfa) (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 6 (IL-6)</measure>
    <time_frame>6 months</time_frame>
    <description>change in interleukin 6 (IL-6) (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte Chemoattractant Protein-1 (MCP-1)</measure>
    <time_frame>6 months</time_frame>
    <description>change in Monocyte Chemoattractant Protein-1 (MCP-1) (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta</measure>
    <time_frame>6 months</time_frame>
    <description>change in Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES)</measure>
    <time_frame>6 months</time_frame>
    <description>change in Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte T</measure>
    <time_frame>6 months</time_frame>
    <description>change in lymphocyte T (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>Child Obesity</condition>
  <condition>Hypertension</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mousse with prebiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mousse without prebiotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties</intervention_name>
    <description>All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vegetable and fruit mousse</intervention_name>
    <description>All children in the control group will consume on daily basis vegetable and fruit mousse for six months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary and physical activity counselling</intervention_name>
    <description>All children in the study will obtain 4 dietary and physical activity advice during the course of the study</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overweight or obesity according to World Health Organization (WHO) definition&#xD;
&#xD;
          -  in 20 patients additionally to overweight or obesity also increase blood pressure&#xD;
&#xD;
          -  in 20 patients additionally to overweight or obesity also liver steatosis&#xD;
&#xD;
          -  willingness to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to mousse components&#xD;
&#xD;
          -  malabsorption syndrome&#xD;
&#xD;
          -  organ failure&#xD;
&#xD;
          -  food neophobia&#xD;
&#xD;
          -  other diseases or health problems which may interfere with study procedures or safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Piotr Socha, MD, PhD</last_name>
    <phone>+48 501065154</phone>
    <email>p.socha@ipczd.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zbigniew Kułaga, MD, PhD</last_name>
    <phone>+48 603547517</phone>
    <email>zakulaga@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Barczynska R, Kapusniak J, Litwin M, Slizewska K, Szalecki M. Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity. Plant Foods Hum Nutr. 2016 Jun;71(2):190-6. doi: 10.1007/s11130-016-0542-9.</citation>
    <PMID>27155867</PMID>
  </results_reference>
  <results_reference>
    <citation>Barczynska R, Bandurska K, Slizewska K, Litwin M, Szalecki M, Libudzisz Z, Kapusniak J. Intestinal Microbiota, Obesity and Prebiotics. Pol J Microbiol. 2015;64(2):93-100. Review.</citation>
    <PMID>26373167</PMID>
  </results_reference>
  <results_reference>
    <citation>Barczynska R, Slizewska K, Litwin M, Szalecki M, Kapusniak J. Effects of dietary fiber preparations made from maize starch on the growth and activity of selected bacteria from the Firmicutes, Bacteroidetes, and Actinobacteria phyla in fecal samples from obese children. Acta Biochim Pol. 2016;63(2):261-6. doi: 10.18388/abp.2015_1068. Epub 2016 Feb 29.</citation>
    <PMID>26929930</PMID>
  </results_reference>
  <results_reference>
    <citation>Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007 Aug;20(8):875-82.</citation>
    <PMID>17679036</PMID>
  </results_reference>
  <results_reference>
    <citation>Litwin M, Michałkiewicz J, Trojanek J, Niemirska A, Wierzbicka A, Szalecki M. Altered genes profile of renin-angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension. 2013 Feb;61(2):431-6. doi: 10.1161/HYPERTENSIONAHA.111.00181. Epub 2012 Dec 24.</citation>
    <PMID>23266543</PMID>
  </results_reference>
  <results_reference>
    <citation>Pinket AS, Van Lippevelde W, De Bourdeaudhuij I, Deforche B, Cardon G, Androutsos O, Koletzko B, Moreno LA, Socha P, Iotova V, Manios Y, De Craemer M; ToyBox-Study Group. Effect and Process Evaluation of a Cluster Randomized Control Trial on Water Intake and Beverage Consumption in Preschoolers from Six European Countries: The ToyBox-Study. PLoS One. 2016 Apr 11;11(4):e0152928. doi: 10.1371/journal.pone.0152928. eCollection 2016.</citation>
    <PMID>27064274</PMID>
  </results_reference>
  <results_reference>
    <citation>Socha P, Grote V, Gruszfeld D, Janas R, Demmelmair H, Closa-Monasterolo R, Subías JE, Scaglioni S, Verduci E, Dain E, Langhendries JP, Perrin E, Koletzko B; European Childhood Obesity Trial Study Group. Milk protein intake, the metabolic-endocrine response, and growth in infancy: data from a randomized clinical trial. Am J Clin Nutr. 2011 Dec;94(6 Suppl):1776S-1784S. doi: 10.3945/ajcn.110.000596. Epub 2011 Aug 17.</citation>
    <PMID>21849603</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Memorial Health Institute, Poland</investigator_affiliation>
    <investigator_full_name>Piotr Socha</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>child</keyword>
  <keyword>prebiotics</keyword>
  <keyword>obesity</keyword>
  <keyword>overweight</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data</ipd_access_criteria>
    <ipd_url>http://czd.pl</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

